T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Public ClinicalTrials.gov record NCT06343311. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of EB103 T-Cell Therapy in Adults With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
Study identification
- NCT ID
- NCT06343311
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Estrella Biopharma, Inc.
- Industry
- Enrollment
- 21 participants
Conditions and interventions
Conditions
- B-Cell Non-Hodgkin's Lymphoma (NHL)
- CNS Lymphoma
- HIV Associated Lymphoma
- High-grade B-cell Lymphoma
- Large B-Cell Lymphoma
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, Non-Hodgkin's, Adult
- Lymphoma, Non-Hodgkins
- Lymphomas Non-Hodgkin's B-Cell
- Non-Hodgkin Lymphoma
- Non-Hodgkin's Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
Interventions
- EB103 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2024
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2027
- Last update posted
- Aug 6, 2025
2024 – 2027
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Davis | Sacramento | California | 95817 | Recruiting |
| Baylor Scott & White Research Institute, Texas Oncology | Dallas | Texas | 75246 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06343311, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2025 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06343311 live on ClinicalTrials.gov.